← All trials
NCT05352542
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 19, 2022
- Primary completion
- Jul 31, 2024
- Completion date
- Oct 31, 2026
- First posted
- Apr 29, 2022
- Last posted
- Jun 14, 2022
- Enrollment
- 34
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- People's Liberation Army of ChinaLead sponsor
- People's Liberation Army of ChinaSponsor investigator
- GenScriptCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.